Ann Murphy, PhD, president and CEO of AlphaMed Press, co-founded the Society for Translational Oncology (STO) in 2000 to fill the gap between the discovery of new oncology treatments and their global translation into oncology practice.
Dr. Murphy is managing editor of The Oncologist®, STO’s official, peer-reviewed journal dedicated to community and hospital-based oncologists entrusted with cancer patient care. Working closely with her editor-in-chief, Bruce Chabner, MD, clinical director emeritus of the Mass General Cancer Center, the journal reaches more than 70,000 readers monthly. Dr. Murphy supports authors throughout the global cancer community by organizing the review and publication of many key papers that advance cancer research.
Dr. Murphy is also the publisher of two other international peer-reviewed journals with globally recognized editorial boards: STEM CELLS®, the world’s first journal devoted to fast-paced stem cell research, and STEM CELLS Translational Medicine®, dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology.
Awarded a doctorate of Philosophy with distinction in Literature from New York University, Dr. Murphy is a published authority on the Irish Literary Renaissance. She serves on the Board of Visitors of the University of North Carolina Lineberger Comprehensive Cancer Center.
“Ann is an extremely talented, selfless and dedicated individual,” says Charles Sanders, MD, retired CEO of Glaxo Wellcome and former general director of Massachusetts General Hospital. “She does not seek self-recognition, but her relentless dedication has markedly enhanced the careers of more than 35 prominent clinical cancer investigators. Furthermore, her synthesis and interpretation of current data has significantly improved the status of cancer research around the world.”
